What is the vericiguat?

vericiguat is Light yellow to yellow solid, while it's Molecular Formula is C19H16F2N8O2. Light yellow to yellow solid Vericiguat is used on targeting cyclic guanosine monophosphate in the treatment of heart failure.

What is the CAS number for vericiguat?

The CAS number of vericiguat is 1350653-20-1.

What is vericiguat (1350653-20-1) used for?

Vericiguat is a novel oral soluble guanylate cyclase (sGC) stimulator.- Soluble guanylate cyclase (sGC) is an enzyme that is activated by nitric oxide (NO). The activation initiates a signaling cascade which converts guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). cGMP levels increase & protein kinase G (PKG) is activated, resulting in a decrease of intracellular free Ca++ -> vascular smooth muscle cell relaxation.- However, individuals with HF have reduced NO levels. Vericiguat, as a sGC stimulator, increases the enzymatic activity of sGC to generate cGMP independently of NO and enhances sGC sensitivity to endogenous NO.Vericiguat is the 2nd drug in this class and follows riociguat ADEMPAS, which has been approved for treating pulmonary arterial hypertension.SOCRATES-REDUCED was a phase II dose-finding trial of vericiguat in HF-rEF. The primary endpoint, change in NTproBNP over 12 weeks, was not statistically significant compared to placebo. A secondary exploratory analysis suggested a dose-response relationship in which higher doses of vericiguat were associated with greater reductions in NTproBNP levels.

What is the vericiguat?

vericiguat is Light yellow to yellow solid, while it's Molecular Formula is C19H16F2N8O2. Light yellow to yellow solid Vericiguat is used on targeting cyclic guanosine monophosphate in the treatment of heart failure.

What is the CAS number for vericiguat?

The CAS number of vericiguat is 1350653-20-1.

What is vericiguat (1350653-20-1) used for?

Vericiguat is a novel oral soluble guanylate cyclase (sGC) stimulator.- Soluble guanylate cyclase (sGC) is an enzyme that is activated by nitric oxide (NO). The activation initiates a signaling cascade which converts guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). cGMP levels increase & protein kinase G (PKG) is activated, resulting in a decrease of intracellular free Ca++ -> vascular smooth muscle cell relaxation.- However, individuals with HF have reduced NO levels. Vericiguat, as a sGC stimulator, increases the enzymatic activity of sGC to generate cGMP independently of NO and enhances sGC sensitivity to endogenous NO.Vericiguat is the 2nd drug in this class and follows riociguat ADEMPAS, which has been approved for treating pulmonary arterial hypertension.SOCRATES-REDUCED was a phase II dose-finding trial of vericiguat in HF-rEF. The primary endpoint, change in NTproBNP over 12 weeks, was not statistically significant compared to placebo. A secondary exploratory analysis suggested a dose-response relationship in which higher doses of vericiguat were associated with greater reductions in NTproBNP levels.

Product Class

1350653-20-1

Product Name：Vericiguat
Molecular Formula：C19H16F2N8O2
Purity：99%
Molecular Weight：426.385

Inquiry

Product Details:

CasNo： 1350653-20-1

Molecular Formula： C19H16F2N8O2

Appearance： Light yellow to yellow solid

Chinese Manufacturer Supply Vericiguat,Sale 1350653-20-1 Efficient Transportation

Molecular Formula:C19H16F2N8O2
Molecular Weight:426.385
Appearance/Colour:Light yellow to yellow solid
Boiling Point:535.9±50.0 °C(Predicted)
PKA:10.61±0.70(Predicted)
PSA：151.08000
Density:1.63±0.1 g/cm3(Predicted)
LogP:3.08240

Vericiguat(Cas 1350653-20-1) Usage

Description

Vericiguat is a medication classified as a soluble guanylate cyclase (sGC) stimulator. It acts by enhancing the activity of the enzyme sGC, which catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). This leads to vasodilation and other beneficial effects in the cardiovascular system.

Uses

Vericiguat is primarily indicated for the treatment of heart failure with reduced ejection fraction (HFrEF). It is prescribed to certain adults who have experienced recent hospitalization for heart failure or who have received intravenous diuretic therapy. Vericiguat aims to reduce the risk of death and the need for hospitalization in these patients by improving cardiac function and alleviating symptoms associated with heart failure.

1350653-20-1 Relevant articles

PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}CARBAMATE

-

Page/Page column 64-65, (2022/01/05)

The present application relates to a nov...

Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure

Follmann, Markus,Ackerstaff, Jens,Redlich, Gorden,Wunder, Frank,Lang, Dieter,Kern, Armin,Fey, Peter,Griebenow, Nils,Kroh, Walter,Becker-Pelster, Eva-Maria,Kretschmer, Axel,Geiss, Volker,Li, Volkhart,Straub, Alexander,Mittendorf, Joachim,Jautelat, Rolf,Schirok, Hartmut,Schlemmer, Karl-Heinz,Lustig, Klemens,Gerisch, Michael,Knorr, Andreas,Tinel, Hanna,Mondritzki, Thomas,Trübel, Hubert,Sandner, Peter,Stasch, Johannes-Peter

, p. 5146 - 5161 (2017/06/28)

The first-in-class soluble guanylate cyc...

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

List of authors. Paul W. Armstrong, M.D., Burkert Pieske, M.D., Kevin J. Anstrom, Ph.D., Justin Ezekowitz, M.B., B.Ch., Adrian F. Hernandez, M.D., M.H.S., Javed Butler, M.D., M.P.H., M.B.A., Carolyn S.P. Lam, M.B., B.S., Ph.D., Piotr Ponikowski, M.D., Adriaan A. Voors, M.D., Ph.D., Gang Jia, Ph.D., Steven E. McNulty, M.S., Mahesh J. Patel, M.D

N Engl J Med 2020; 382:1883-1893

In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction of less than 45% to receive vericiguat (target dose, 10 mg once daily) or placebo, in addition to guideline-based medical therapy.

USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES

-

Paragraph 0156-0161, (2013/06/28)

The present invention relates to the nov...

1350653-20-1 Upstream products

113237-20-0
2,6-dichloro-5-fluoropyridine-3-carboxamide
1350653-30-3
2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidine-4,5,6-triamine
79-22-1
methyl chloroformate
82671-02-1
2,6-dichloro-5-fluoro-pyridine-3-carbonitrile

1350653-20-1 Downstream products

1350653-21-2
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate
1350653-22-3
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}(2,2,2-trifluoroethyl)carbamate
1350659-01-6
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate maleate
1350658-99-9
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate mesylate

Relevant Products

Pralsetinib
CAS：2097132-94-8
Azacitidine
CAS：320-67-2
Ubrogepant
CAS：1374248-77-7